Analytical Validation Commences Ahead of FDA 510(k) Submission
On 13 October 2026, Cleo Diagnostics (ASX:COV) announced the commencement of Analytical Validation (AV) of its Pre-Surgical Ovarian Cancer Test. The company described it as the first formal regulatory study of its commercial assay ahead of a planned FDA 510(k) submission in H1 CY2027.
The start of AV marks the company’s transition from assay development and optimisation into formal validation testing under a prescriptive FDA framework. The program is intended to establish the analytical performance of the test and generate the dataset required to support subsequent Clinical Validation (CV) and the FDA submission.
Commencement follows receipt of the first production batch of 125 test kits manufactured by Bio-Techne (NASDAQ:TECH), as referenced in the ASX announcement dated 3 September 2026. It also follows completion of Cleo’s internal documentation and pre-validation activities required before formal testing.
When big ASX news breaks, our subscribers know first
What the Analytical Validation Program Involves
Three batches, one goal
Cleo will evaluate three independently manufactured production batches of its commercial test kits. Testing will assess key analytical performance characteristics across the batches, with the aim of demonstrating the following:
- Precision
- Reproducibility
- Manufacturing consistency
- Overall analytical robustness
The company stated this will generate the analytical evidence required to support progression into CV. AV is being conducted predominantly in-house using Bio-Techne’s Ella™ automated immunoassay platform.
The commercial assay being validated is built on an eight-biomarker panel, expanded from five analytes and designed for the Ella platform so it can be deployed across existing diagnostic laboratory infrastructure.
Timing
The second and third batches of test kits are estimated to be received in November 2026. AV is expected to take ~3 months.
| Item | Detail | Timing |
| First production batch | **125 test kits** from Bio-Techne | Received |
| Second and third batches | Remaining two of **three batches** | Estimated **November 2026** |
| Analytical Validation duration | Testing across three batches | Expected **~3 months** |
| FDA 510(k) submission | Planned submission | **H1 CY2027** |
The timing figures are estimates, as presented by the company. They give investors defined near-term checkpoints to track.
Why Analytical Validation Matters for Investors
A plain-English explainer
Analytical validation tests whether a diagnostic test measures what it claims to measure, consistently and reliably, including across different kit batches. Clinical validation is a separate step, which tests how the test performs on patient samples.
An FDA 510(k) submission is a premarket notification made to the US Food and Drug Administration. The announcement does not address the likelihood of any particular regulatory outcome.
For investors, the AV program is the stage at which the data on manufacturing consistency and analytical robustness of the commercial assay is generated. Cleo described this data as an important component of its planned FDA 510(k) submission.
Cleo’s technology is based on the CXCL10 biomarker, which the company says is produced early and at high levels in ovarian cancer but is largely absent in benign disease. According to the company, ovarian cancer has the highest five-year mortality rate of all cancers affecting women, with 51% of patients dying within five years.
Remaining Pathway to FDA Submission
In parallel to AV, Cleo will progress to Clinical Validation to test its pivotal U.S. clinical trial and control samples. With AV now underway, the company’s remaining major milestones prior to FDA submission are:
The clinical samples for Clinical Validation come from the pivotal U.S. trial, which enrolled 624 women across 19 sites and yielded 514 usable blood samples, comfortably above the 500-participant minimum.
- Analytical Validation (including testing of three production batches)
- Finalisation of the commercial assay algorithm
- Clinical Validation (including testing of pivotal clinical trial and control samples)
- Clinical data analysis and trial results
- FDA 510(k) submission
Cleo is executing a staged development strategy, starting with a pre-surgical triage test, then expanding into recurrence monitoring and ultimately global screening. The company states it is currently conducting its pivotal clinical trial, with FDA submission and commercial launch expected next year.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare and biotech updates the moment market-moving announcements break.